Literature DB >> 16275171

Cystic fibrosis mutations and genotype-pulmonary phenotype analysis.

Andrew T Braun1, Philip M Farrell, Claude Ferec, Marie Pierre Audrezet, Anita Laxova, Zhanhai Li, Michael R Kosorok, Marjorie A Rosenberg, William M Gershan.   

Abstract

BACKGROUND: Although there are more than 1000 mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, most of them are uncommon and only limited information exists regarding genotype-pulmonary phenotype relationships.
METHODS: We determined and classified the CFTR mutations using denaturing high-performance liquid chromatography and developed new, quantitative methods to categorize pulmonary phenotypes.
RESULTS: Two novel alleles were discovered, namely G1047R and 1525-2A-->G, which were accompanied by F508del and G551D mutations, respectively. Assessment of numerous options revealed that CF pulmonary phenotype categorization in children cannot be accomplished with clinical or pulmonary function data but is facilitated by longitudinal quantitative chest radiology. It was most useful to categorize pulmonary disease status by evaluating the typical pattern of abnormalities in patients homozygous for the F508del mutation, and then compare patients with minor mutations to this typical CF pulmonary phenotype. By this method, both patients with novel mutations have pulmonary phenotypes typical of F508del homozygotes. However, patients with class IV mutations (e.g., R347P) or with pancreatic sufficiency showed serial chest radiographs that were atypically mild.
CONCLUSIONS: Longitudinal quantitative chest radiography provides a new strategy for CF pulmonary phenotype categorization that should be useful for genotype-phenotype delineation in individual patients and in both epidemiologic studies and clinical trials involving groups of children with CF.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16275171     DOI: 10.1016/j.jcf.2005.09.008

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  14 in total

1.  Optimal DNA tier for the IRT/DNA algorithm determined by CFTR mutation results over 14 years of newborn screening.

Authors:  Mei W Baker; Molly Groose; Gary Hoffman; Michael Rock; Hara Levy; Philip M Farrell
Journal:  J Cyst Fibros       Date:  2011-03-08       Impact factor: 5.482

Review 2.  Adopting orphans: comprehensive genetic testing of Mendelian diseases of childhood by next-generation sequencing.

Authors:  Stephen F Kingsmore; Darrell L Dinwiddie; Neil A Miller; Sarah E Soden; Carol J Saunders
Journal:  Expert Rev Mol Diagn       Date:  2011-11       Impact factor: 5.225

3.  Newborn screening for cystic fibrosis: parents' preferences regarding counseling at the time of infants' sweat test.

Authors:  Audrey Tluczek; Rebecca L Koscik; Peggy Modaff; Darci Pfeil; Michael J Rock; Philip M Farrell; Caroline Lifchez; Mary Ellen Freeman; William Gershan; Christina Zaleski; Bradley Sullivan
Journal:  J Genet Couns       Date:  2006-08       Impact factor: 2.537

Review 4.  Background and Epidemiology.

Authors:  Don B Sanders; Aliza K Fink
Journal:  Pediatr Clin North Am       Date:  2016-08       Impact factor: 3.278

5.  Pulmonary outcome differences in U.S. and French cystic fibrosis cohorts diagnosed through newborn screening.

Authors:  Aimee C Walsh; Gilles Rault; Zhanhai Li; Virginie Scotet; Ingrid Duguépéroux; Claude Férec; Michel Roussey; Anita Laxova; Philip M Farrell
Journal:  J Cyst Fibros       Date:  2009-11-18       Impact factor: 5.482

6.  Association between mucoid Pseudomonas infection and bronchiectasis in children with cystic fibrosis.

Authors:  Philip M Farrell; Jannette Collins; Lynn S Broderick; Michael J Rock; Zhanhai Li; Michael R Kosorok; Anita Laxova; William M Gershan; Alan S Brody
Journal:  Radiology       Date:  2009-08       Impact factor: 11.105

7.  Risk factors for the progression of cystic fibrosis lung disease throughout childhood.

Authors:  Don B Sanders; Zhanhai Li; Anita Laxova; Michael J Rock; Hara Levy; Jannette Collins; Claude Ferec; Philip M Farrell
Journal:  Ann Am Thorac Soc       Date:  2014-01

Review 8.  Newborn screening for cystic fibrosis: a lesson in public health disparities.

Authors:  Lainie Friedman Ross
Journal:  J Pediatr       Date:  2008-09       Impact factor: 4.406

9.  Refining the continuum of CFTR-associated disorders in the era of newborn screening.

Authors:  H Levy; M Nugent; K Schneck; D Stachiw-Hietpas; A Laxova; O Lakser; M Rock; M K Dahmer; J Biller; S Z Nasr; M Baker; S A McColley; P Simpson; P M Farrell
Journal:  Clin Genet       Date:  2016-01-20       Impact factor: 4.438

10.  Early Life Growth Trajectories in Cystic Fibrosis are Associated with Pulmonary Function at Age 6 Years.

Authors:  Don B Sanders; Aliza Fink; Nicole Mayer-Hamblett; Michael S Schechter; Gregory S Sawicki; Margaret Rosenfeld; Patrick A Flume; Wayne J Morgan
Journal:  J Pediatr       Date:  2015-09-02       Impact factor: 4.406

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.